Trials / Not Yet Recruiting
Not Yet RecruitingNCT07512050
Oral Lactobacillus Reuteri for Skin Barrier Dysfunction in Obesity
A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of Oral Lactobacillus Reuteri in Treating Skin Barrier Function Impairment Caused by Obesity.
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 140 (estimated)
- Sponsor
- Shenzhen People's Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Accepted
Summary
This clinical trial aims to evaluate the safety and efficacy of oral Lactobacillus reuteri supplementation for treating obesity-induced skin barrier impairment in individuals aged 18-40 with a BMI ≥30. The study focuses on the following questions: Can oral Lactobacillus reuteri supplementation reduce skin barrier damage (measured by transepidermal water loss/TEWL) in obese participants? Does modulation of gut microbiota with Lactobacillus reuteri impact skin barrier function and systemic inflammation? Researchers will compare outcomes across two groups: Intervention Group (Obese): Oral Lactobacillus reuteri capsules. Placebo Control Group (Obese): Oral inactive (heat-killed) Lactobacillus reuteri. Participant Procedures: Take daily oral capsules (Lactobacillus reuteri or inactive strain) for 4 weeks. Undergo non-invasive skin testing (TEWL measurements) at baseline and study completion. Provide stool and samples for analyses. Complete weekly check-ins to report adverse effects (e.g., gastrointestinal discomfort, skin irritation).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Oral Lactobacillus reuteri group | 1×10\^11 CFU of inactive Lactobacillus reuteri was given orally once daily for one month |
| BIOLOGICAL | Oral administration of inactive Lactobacillus reuteri group | 1×10\^11 CFU of inactive Lactobacillus reuteri was given orally once daily for one month |
Timeline
- Start date
- 2026-04-10
- Primary completion
- 2026-06-28
- Completion
- 2026-07-30
- First posted
- 2026-04-06
- Last updated
- 2026-04-06
Source: ClinicalTrials.gov record NCT07512050. Inclusion in this directory is not an endorsement.